




## MONIKA KLAJN

SENIOR ASSOCIATE

[London](#)

Monika is a patent litigator with particular expertise in pharmaceuticals and life sciences sector.

 +44 20 7466  
7604

 [Monika.Klajn@hsf.com](mailto:Monika.Klajn@hsf.com)

---

## BACKGROUND

Monika graduated with a law degree from Cambridge University and completed LLM degree at Cambridge University (1st) specialising in commercial law and intellectual property. She has completed her Postgraduate Diploma in IP Law and Practice at the University of Oxford.

Monika is admitted as a solicitor in England & Wales and in Ireland.

## PUBLICATIONS

- [Supreme Court hears Kymab's appeal against the sufficiency findings of the Court of Appeal](#)
- [Novelty - what needs to be enabled? A closer look at \*Takeda v Roche\*](#)
- [Who has jurisdiction and who decides who has jurisdiction - the Court of Appeal ruling in \*Ablynx v VHSquared\*](#)
- [Striking the limits of Arrow declarations?](#)

---

## EXPERIENCE

Monika has worked on a range of contentious patent matters with a particular focus in the pharmaceutical and life sciences sector. Monika has acted for a variety of clients in all stages of disputes, including interim applications, main action proceedings and appeals before the UK Court. Monika has also worked on matters involving coordination of multi-jurisdictional patent litigation and has formed excellent relationships with IP counsel in numerous firms across Europe.

Monika also regularly provides pro bono assistance to a variety of clients, including advising UNHCR on the intellectual property aspects of its ground-breaking MADE51 initiative.

Monika's experience includes advising:

- AbbVie in United Kingdom and multi-jurisdictional patent litigation regarding its leading its blockbuster anti-TNF $\alpha$  antibody Humira® (adalimumab)
- The United Nations High Commissioner for Refugees in relation to the launch of its global consumer goods platform MADE51 and the establishment of its UK-based charity
- A molecular diagnostics company in relation to its pan-European strategy in preparation for commercialisation of its diagnostics product
- A global pharmaceutical company on strategy and multi-jurisdictional coordination of potential litigation in respect of a new drug in the haematology space
- Abcam on the intellectual property aspects of its acquisition of Expeleon AG's proteomics and immunology business

## ACCOLADES

- Commended for Pro Bono Initiative of the Year at The Lawyer Awards 2019 for MADE51 project
- PILnet award for 'Exemplary Partnership in the Public Interest' (2019) in respect of MADE51 project